Inicio038290 • KOSDAQ
add
Macrogen Inc
Cierre anterior
15.360,00 ₩
Intervalo diario
15.260,00 ₩ - 15.530,00 ₩
Intervalo anual
14.700,00 ₩ - 24.600,00 ₩
Cap. bursátil
167,61 mil M KRW
Volumen medio
11,44 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
1,94 %
Bolsa de valores principal
KOSDAQ
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (KRW) | mar 2025info | Cambio interanual |
|---|---|---|
Ingresos | 40,96 mil M | 29,46 % |
Gastos operativos | 16,98 mil M | 24,32 % |
Ingresos netos | -2218,91 M | -3,18 % |
Margen de beneficio neto | -5,42 | 20,29 % |
Beneficios por acción | — | — |
EBITDA | -346,40 M | -122,27 % |
Tipo impositivo efectivo | 1,39 % | — |
Balance general
Activos totales
Responsabilidades totales
| (KRW) | mar 2025info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 43,70 mil M | 99,38 % |
Activos totales | 332,81 mil M | 26,75 % |
Responsabilidades totales | 161,36 mil M | 50,90 % |
Patrimonio total | 171,45 mil M | — |
Acciones en circulación | 10,84 M | — |
Precio-valor contable | 1,07 | — |
Rentabilidad económica | -2,30 % | — |
Retorno sobre capital | -3,02 % | — |
Flujo de caja
Variación neta del flujo de caja
| (KRW) | mar 2025info | Cambio interanual |
|---|---|---|
Ingresos netos | -2218,91 M | -3,18 % |
Efectivo de operaciones | 362,70 M | 109,97 % |
Efectivo de inversión | -8904,29 M | -43,15 % |
Efectivo de financiación | 5058,78 M | 14,81 % |
Variación neta del flujo de caja | -3062,05 M | 33,91 % |
Flujo de caja libre | -2123,25 M | 88,42 % |
Información sobre la empresa
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Director ejecutivo
Fundación
5 jun 1997
Sitio web
Empleados
500
